SNAI2 and ovarian carcinoma: Furthermore, the anti-tumor and pro-ferroptosis effects of erastin on ovarian cancer in vivo were partially weakened by SNAI2 overexpression, further verifying the critical role of SNAI2-mediated ferroptosis in ovarian cancer progression.